Tuesday, January 20, 2026
  • Advertise
  • Recruitment
  • Contact us:
  • Register
Irish Pharmacy News
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
Irish Pharmacy News

Actase Lutein ZA

IPN by IPN
23 October 2020
in Product News
0
Actase Lutein ZA

 

Support your eyesight with Actase Lutein ZA, a scientifically formulated eye health supplement bursting with vitamins and minerals including zinc, copper and  Vitamins C & E. Only 1x capsule a day, Actase Lutein ZA is the perfect supplement addition to your daily routine.

For more information visit www.scopeyecare.com

Previous Post

Can health and business collaborations help Ireland survive the pandemic?

Next Post

No ‘Grey’ Days at Grays Pharmacy

Next Post
No ‘Grey’ Days at Grays Pharmacy

No ‘Grey’ Days at Grays Pharmacy

ALONE Urges Government to Reconsider Pharmacy Changes Including Blister Packs

ALONE Urges Government to Reconsider Pharmacy Changes Including Blister Packs

16 December 2025
Migraine Ireland launches the Irish Headache Society to advance migraine and headache care in Ireland.

Migraine Ireland Launches First Multidisciplinary Irish Headache Society

8 December 2025
Boots Ireland launches Common Conditions Service allowing pharmacists to prescribe for the first time.

Boots Ireland Unveils Groundbreaking Common Conditions Service, Empowering Pharmacists to Prescribe for the First Time

8 December 2025

RECOMMENDED NEWS

From The Great Resignation to The Great Retention – The Hunt for Talent

From The Great Resignation to The Great Retention – The Hunt for Talent

4 years ago
CPD: Overactive Bladder

CPD: Overactive Bladder

3 years ago
GSK plc has announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with Shingrix (Recombinant Zoster Vaccine or RZV). The final trial data demonstrate that RZV maintains efficacy against shingles for more than a decade in adults over 50. The data presented at the European Congress of Clinical Microbiology and Infectious Diseases (ESCMID) in Barcelona, Spain (27–30 April 2024) is based on the ZOSTER-049 study.1

New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade

2 years ago

RCSI research finds air pollution in Ireland associated with strokes

5 years ago

test-sponsored-ad-jan-2026

Tweets by Irish_PharmNews

Quick links

  • About
  • Advertise
  • Careers
  • Contact us

Other info

  • Contact us
  • Register for Digital Magazines
  • Privacy Policy
  • About
  • Advertise
  • Careers
  • Contact us

© 2024 IPN

  • Login

    Forgot password? | Register

    Register

    Registration confirmation will be emailed to you.

    Login | Forgot password?

    Reset Password

    Please enter your username or email address. You will receive a link to create a new password via email.

    Login

Login

Register

Forgotten Password?

Register | Lost your password?
| Back to Login
No Result
View All Result
  • News
  • Learning
  • Other
    • Conferencing
    • Developments
    • Product News
    • Profiles
    • Research
  • Digital Magazines (IPN Online Issues Older Issue Tabs)
  • Awards

© 2024 IPN